Integrated invitro testing system

In Vivo reproductive and developmental toxicity assessment requires the use of a large number of animals. Identifying potential reproductive toxicity at an early stage in drug discovery and chemical safety can save both time and developmental costs, and most importantly reduce the likelihood of late-stage failure.

ReproTox is the ideal partner to assist you in understanding the toxic liability of your compounds using a panel of different techniques. We can help identify which compounds have the safety profile to advance into the market. Our advanced technology and automation allow for high quality data to be generated rapidly, reliable, and cost-effectively.

ReproTox has invested in a High- Content screening (HCS) platform that uses automated fluorescence imaging to simultaneously analyze multi-parametric indicators of cytotoxicity and potential mechanism. This improves the prediction of toxicological events and allows for a better understanding of the mechanisms of drug/compound toxicity.

ReproTox serves the Pharmaceutical and Biotech, Cosmetics/Personal Care and Chemicals Industries as well as academia and non-profit organizations. We focus heavily on R&D and our goal is to continually develop and improve approaches to more accurately predict adverse outcomes following exposure to a drug or chemical using robust In Vitro methods combined with In Silico technology.

ReproTox through our expertise has developed a novel In Vitro 3D culture model using testicular cells. This system allows the study of male reproductive health with respect to various toxicants without the need for In Vivo subjects. Our products are centered around this model and our research team continually works to improve this model, and works with clients to translate their project objectives into research plans.

3D testis model
Immunofluorescence of the testicular cell coculture with cell-type-specific protein markers at 48h (A) and 72h (B) postinoculation. Spermatogonial cells are labeled with a specific mouse GCNA1(pink); Leydig cells are labeled with StAR (red staining, black arrow); and Sertoli cells are labeled with neither GCNA1 nor StAR(white arrow). Treatment with BPA, BPS, and BPAF. (C) induced alteration of Cytosketch and induction of DNA damages (γ-H2Ax).

ReproTox uses Adverse Outcome Pathways (AOPs) as a tool for the design of testing strategies to support the efficacy and safety assessment for the In Vitro assays.

HCA work flow

Machine Learning-Based High- Content Single Cell Analysis

We developed a machine learning-based HCA pipeline to examine the multiplexed phenotypic changes associated with Adverse Outcome Pathways (AOPs), including nuclear morphology, DNA synthesis, DNA damage, and cytoskeletal structure in a single-cell-based analysis, which can provide a rapid and objective High-Throughput screening in the fields of efficacy/ toxicity testing, medical imaging, and disease diagnosis.

Machine Learning